Skip to content
Homepage
Author:
TORREY PINES INVESTMENT
Posted Date:
April 30, 2026
Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia Computational Advances in Drug Discovery
TORREY PINES INVESTMENT
April 30, 2026
Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting
TORREY PINES INVESTMENT
April 16, 2026
Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
TORREY PINES INVESTMENT
March 17, 2026
